Company: SMNR
Filing Date: 2025-04-02
Form Type: 10-K
Source: 0001213900-25-027319
Chunk: 604

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-02
Form: 10-K
Item: Item 3
Chunk 604
---

because of changes in conditions, or that the degree or compliance with the policies or procedures may deteriorate. Management, including
our Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting
at December 31, 2024. In making these assessments, management used the criteria set forth by the Committee of Sponsoring Organizations
of the Treadway Commission (COSO) in Internal Control - Integrated Framework (2013). Based on our assessments and those criteria, management
determined that we maintained effective internal control over financial reporting as of December 31, 2024.

This
Report on does not include an attestation report of internal controls from our independent registered public accounting firm due to our
status as an emerging growth company under the JOBS Act.

Changes
in Internal Control over Financial Reporting

During
the quarter ended December 31, 2024, there has been no change in our internal control over financial reporting that has materially affected,
or is reasonably likely to materially affect, our internal control over financial reporting.

Item
9B. Other Information.

Not
applicable.

Item
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

Not
applicable.

23

PART
III

Item
10. Directors, Executive Officers and Corporate Governance.

Directors
and Executive Officers

Our
directors and executive officers are as follows:

    Name
     
    Age
     
    Title
  
    Lei
    Huang
     
    53
     
    Chief
    Executive Officer and Director
  
    You
    (“Patrick”) Sun
     
    37
     
    Chief
    Financial Officer
  
    Huifeng
    Chang
     
    59
     
    Director
  
    Jim
    Mao
     
    57
     
    Director
  
    Kevin
    Vassily
     
    58
     
    Director

Lei Huang, Chief Executive Officer and Director

Mr. Huang has served as our director and Chief Executive Officer
since its inception. Mr. Huang has also served as a member of the board of directors of US Tiger Securities, Inc. (“US Tiger”)
since December 2019 and previously served as a director of its parent company, UP Fintech Holding Limited (Nasdaq: TIGR), from November
2020 until June 2022. Since December 2021, Mr. H